Low-volume polyethylene glycol ascorbate solution (PLENVUTM) – a new generation of intestinal cleansers with high efficiency and good tolerance
Drug profileGastroent Hepatol 2022; 76(2): 153–154. doi: 10.48095/ccgh2022153
Literaturepdf Milan LukášJaká je optimální strategie léčby u komplikovaného průběhu Crohnovy nemoci na tenkém střevě?
Answer to the quizGastroent Hepatol 2022; 76(2): 172.
pdf Milan LukášSome notes on mesalazine treatment in patients with ulcerative colitis and Crohn‘s disease
CommentsGastroent Hepatol 2022; 76(3): 248–249.
Literaturepdf Milan LukášThe benefit of biosimilar monoclonal antibodies in the therapy of inflammatory bowel diseases
CommentGastroent Hepatol 2022; 76(5): 447–452. doi: 10.48095/ccgh2022447
SummaryLiteraturepdf Milan LukášTwo years of the COVID-19 pandemic in the population of Czech patients with inflammatory bowel disease treated with biological therapy – experience of the tertiary IBD center
Original articleGastroent Hepatol 2023; 77(1): 14–20. doi: 10.48095/ccgh202314
SummaryLiteraturepdf Karin Černá , Milan LukášOn the question of the interchangeability of monoclonal biosimilar antibodies in the treatment of immune-mediated inflammatory diseases
CommentGastroent Hepatol 2023; 77(1): 34–37. doi: 10.48095/ccgh202334
Literaturepdf Milan Lukáš, Ladislav Šenolt, Spyridon GkalpakiotisFilgotinib in the treatment of inflammatory bowel diseases
Drug profileGastroent Hepatol 2023; 77(2): 145–146. doi: 10.48095/ccgh2023145
Literaturepdf Milan LukášBowel preparation before colonoscopy – comparison of bowel cleansing quality and patient’s tolerance of several bowel cleansing devices
Review articleGastroent Hepatol 2023; 77(3): 237–242. doi: 10.48095/ccgh2023237
SummaryLiteraturepdf Jindra Reissigová, Milan Lukáš